Support teaching, research, and patient care.
Dr Rahul P. Sharma, MBBS, FRACP is the Director of Structural Interventions at Stanford Healthcare, Associate Director of the Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine at Stanford University. Dr Sharma graduated from Monash University and completed his medicine and cardiology training at the Alfred Hospital in Melbourne, Australia. He completed an advanced interventional and structural fellowship at Cedars Sinai Medical Center in Los Angeles, California in 2015 before joining Cedars Sinai as Clinical Faculty, Director of the Structural Imaging Core Laboratory and Associate Director of Interventional Cardiology Research until 2019, before joining Stanford Healthcare. Dr Sharma is an Interventional Cardiologist with specialized clinical and research interests in structural heart disease, particularly transcatheter valve therapy. He has a large volume of expertise in transcatheter aortic, mitral and tricuspid replacement, percutaneous mitral valve repair, left atrial appendage occlusion, PFO/ASD/VSD closure, alcohol septal ablation and cerebral protection. He also has expertise in CT imaging for structural heart disease. He is a clinical investigator in ongoing national multi-center research studies and clinical trials and has co-authored numerous peer reviewed, scientific articles and book chapters. Dr Sharma also serves as a national and international clinical proctor for transcatheter aortic and mitral valve implantation and percutaneous mitral valve repair and speaks regularly at major national and international cardiology meetings.
Transcatheter valve therapies, CT valve imaging, AI and device innovation
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
The objective of this study is to establish the safety and effectiveness of the Edwards
SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific
aortic stenosis (AS).
View full details
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 /
SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with
moderate, calcific aortic stenosis.
TRISCEND II Pivotal Trial
Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System
in patients with symptomatic severe tricuspid regurgitation who have been determined to be at
an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the
cardiac surgeon with concurrence by the local Heart Team
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of
MitraClip™ device versus surgical repair in patients with severe primary MR who are at
moderate surgical risk and whose mitral valve has been determined to be suitable for
correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts:
Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral
Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort
will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in
the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the
Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral
Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne
Transcatheter Mitral Valve System for the treatment of patients with symptomatic,
moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral
valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and
clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip
System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation,
within approved MitraClip indications. In addition, the safety and effectiveness of the
Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral
annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are
not suitable for mitral valve surgery for reasons other than severe mitral annular
calcification and are also not suitable for transcatheter repair with MitraClip, will be
enrolled in the Non-repairable cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6
months, and annually through 5 years.
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for
transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis
who are indicated for TAVR.
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair
System in patients with degenerative mitral regurgitation (DMR) who have been determined to
be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with
functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All
subjects enrolled with receive the study device.
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve
(THV) in patients with severe, calcific aortic stenosis who are at low operative risk for
standard aortic valve replacement.
2019-06 TRISCEND Study
Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE
Tricuspid Valve Replacement System